Published in Neuropharmacology on December 12, 2015
Role of extracellular cysteine residues in the adenosine A2A receptor. Purinergic Signal (2016) 0.78
A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain. Sci Rep (2016) 0.77
Extracellular purines, purinergic receptors and tumor growth. Oncogene (2016) 0.76
Ocular Purine Receptors as Drug Targets in the Eye. J Ocul Pharmacol Ther (2016) 0.75
Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT). Purinergic Signal (2016) 0.75
2',3'-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents. Purinergic Signal (2016) 0.75
The P2X7 Receptor-Interleukin-1 Liaison. Front Pharmacol (2017) 0.75
ATP-induced Ca(2+)-signalling mechanisms in the regulation of mesenchymal stem cell migration. Cell Mol Life Sci (2017) 0.75
ATP evokes Ca(2+) signals in cultured foetal human cortical astrocytes entirely through G protein-coupled P2Y receptors. J Neurochem (2017) 0.75
Purinergic Signalling: Therapeutic Developments. Front Pharmacol (2017) 0.75
P2X7 receptor large pore signaling in avian Müller glial cells. J Bioenerg Biomembr (2017) 0.75
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
Structure of an agonist-bound human A2A adenosine receptor. Science (2011) 6.21
P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature (2003) 6.04
The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci (2006) 4.93
Crystal structure of the ATP-gated P2X(4) ion channel in the closed state. Nature (2009) 4.18
UDP acting at P2Y6 receptors is a mediator of microglial phagocytosis. Nature (2007) 3.78
Structural basis for allosteric regulation of GPCRs by sodium ions. Science (2012) 3.40
Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci (2010) 3.38
P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels. EMBO J (1998) 3.23
Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci (2007) 3.01
Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature (2000) 2.85
Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature (2012) 2.53
P2X2 knockout mice and P2X2/P2X3 double knockout mice reveal a role for the P2X2 receptor subunit in mediating multiple sensory effects of ATP. J Physiol (2005) 2.25
A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A (2002) 2.24
Pharmacology of P2X channels. Pflugers Arch (2006) 2.14
Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev (2011) 2.14
Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal (2012) 2.13
Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol (1996) 2.10
Adenosine inhibits tumor necrosis factor-alpha release from mouse peritoneal macrophages via A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther (2005) 2.03
A G protein-coupled receptor for UDP-glucose. J Biol Chem (2000) 1.91
A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol (1994) 1.87
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol (1995) 1.81
Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov (2013) 1.74
P2 receptors activated by uracil nucleotides--an update. Curr Med Chem (2006) 1.62
Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature (2014) 1.60
A2A-adenosine receptor reserve for coronary vasodilation. Circulation (1998) 1.55
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
P2X4R+ microglia drive neuropathic pain. Nat Neurosci (2012) 1.51
The life and times of ivermectin - a success story. Nat Rev Microbiol (2004) 1.49
ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol (2000) 1.44
Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today (2011) 1.44
The P2X7 receptor channel: recent developments and the use of P2X7 antagonists in models of disease. Pharmacol Rev (2014) 1.39
Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol (2004) 1.38
Agonist-bound structure of the human P2Y12 receptor. Nature (2014) 1.36
Painful purinergic receptors. J Pharmacol Exp Ther (2007) 1.33
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett (2007) 1.33
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther (2004) 1.31
Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med (2011) 1.28
Two disparate ligand-binding sites in the human P2Y1 receptor. Nature (2015) 1.25
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem (2012) 1.23
Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states. Brain (2014) 1.21
Quantification of Gi-mediated inhibition of adenylyl cyclase activity reveals that UDP is a potent agonist of the human P2Y14 receptor. Mol Pharmacol (2009) 1.20
Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med (2005) 1.19
Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis (2012) 1.19
Purinergic signalling and cancer. Purinergic Signal (2013) 1.18
Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol Pharmacol (2004) 1.18
Structure-activity relationships of dinucleotides: Potent and selective agonists of P2Y receptors. Purinergic Signal (2005) 1.16
Allosteric modulation of ATP-gated P2X receptor channels. Rev Neurosci (2011) 1.16
A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs (2008) 1.15
Electrophilic derivatives of purines as irreversible inhibitors of A1 adenosine receptors. J Med Chem (1989) 1.13
Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol (2012) 1.13
The suramin analogue NF279 is a novel and potent antagonist selective for the P2X(1) receptor. Neuropharmacology (2000) 1.12
Contributions of P2X3 homomeric and heteromeric channels to acute and chronic pain. Expert Opin Ther Targets (2003) 1.09
ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties. II. In vivo characterization in the rat. J Pharmacol Exp Ther (2000) 1.09
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J Med Chem (2009) 1.07
AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol (2010) 1.07
P2X4 receptors influence inflammasome activation after spinal cord injury. J Neurosci (2012) 1.05
Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors. Neuropharmacology (1999) 1.05
Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem (2004) 1.03
Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol (2006) 1.03
Phosphoinositides regulate P2X4 ATP-gated channels through direct interactions. J Neurosci (2008) 1.03
A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem (1998) 1.02
A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br J Pharmacol (2010) 1.02
Involvement of the P2X7 purinergic receptor in inflammation: an update of antagonists series since 2009 and their promising therapeutic potential. Curr Med Chem (2015) 1.02
Enduring reversal of neuropathic pain by a single intrathecal injection of adenosine 2A receptor agonists: a novel therapy for neuropathic pain. J Neurosci (2009) 1.01
Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. Am J Respir Cell Mol Biol (2004) 1.00
Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. Pharmacol Ther (2012) 1.00
A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Mol Pharmacol (2013) 1.00
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00
Hetero-oligomerization of the P2Y11 receptor with the P2Y1 receptor controls the internalization and ligand selectivity of the P2Y11 receptor. Biochem J (2008) 1.00
P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat (2010) 0.99
Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol (2011) 0.99
Medicinal chemistry of P2X receptors: allosteric modulators. Curr Med Chem (2015) 0.98
P2 receptors and platelet function. Purinergic Signal (2011) 0.98
Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor. Mol Pharmacol (2015) 0.96
Metabotropic P2Y1 receptor signalling mediates astrocytic hyperactivity in vivo in an Alzheimer's disease mouse model. Nat Commun (2014) 0.96
Subtype-specific regulation of P2X3 and P2X2/3 receptors by phosphoinositides in peripheral nociceptors. Mol Pain (2009) 0.96
Rational design of sulfonated A3 adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. J Med Chem (2013) 0.96
In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signal (2011) 0.96
NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther (2009) 0.95
Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief. Mol Pain (2009) 0.95
Exploring the ATP-binding site of P2X receptors. Front Cell Neurosci (2013) 0.95
In vivo phenotypic screening for treating chronic neuropathic pain: modification of C2-arylethynyl group of conformationally constrained A3 adenosine receptor agonists. J Med Chem (2014) 0.94
Investigation of the effects of P2 purinoceptor ligands on the micturition reflex in female urethane-anaesthetized rats. Br J Pharmacol (2004) 0.93
Conserved extracellular cysteines differentially regulate the inhibitory effect of ethanol in rat P2X4 receptors. Biochem Biophys Res Commun (2009) 0.92
Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a. Neuron (2015) 0.92
Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity. J Med Chem (2012) 0.92
Direct modulation of P2X1 receptor-channels by the lipid phosphatidylinositol 4,5-bisphosphate. Mol Pharmacol (2008) 0.92
N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists. J Med Chem (2012) 0.92
The stable pyrimidines UDPbetaS and UTPgammaS discriminate between contractile cerebrovascular P2 receptors. Eur J Pharmacol (2003) 0.92
P2X receptors and inflammation. Curr Med Chem (2015) 0.92
P2Y purinergic receptors: new targets for analgesic and antimigraine drugs. Biochem Pharmacol (2012) 0.91
Allosteric interactions between agonists and antagonists within the adenosine A2A receptor-dopamine D2 receptor heterotetramer. Proc Natl Acad Sci U S A (2015) 0.91
2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. Biochem Pharmacol (2004) 0.91
Involvement of P2X4 receptors in hippocampal microglial activation after status epilepticus. Glia (2013) 0.91
Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y(14). Bioorg Med Chem Lett (2010) 0.91
Interaction of Approved Drugs with Synaptic Vesicle Protein 2A. Arch Pharm (Weinheim) (2017) 0.75
Angiotensin II type 1/adenosine A 2A receptor oligomers: a novel target for tardive dyskinesia. Sci Rep (2017) 0.75